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Abstract—Amiodarone is the most effective antiarrhythmic drug for maintaining sinus rhythm for patients with atrial
fibrillation. Extra-cardiac side effects have been a limiting factor, especially during chronic use, and may offset its
benefits. Dronedarone is a noniodinated benzofuran derivative of amiodarone that has been developed for the treatment
of atrial fibrillation and atrial flutter. Similar to amiodarone, dronedarone is a potent blocker of multiple ion currents,
including the rapidly activating delayed-rectifier potassium current, the slowly activating delayed-rectifier potassium
current, the inward rectifier potassium current, the acetylcholine activated potassium current, peak sodium current, and
L-type calcium current, and exhibits antiadrenergic effects. It has been studied for maintenance of sinus rhythm and
control of ventricular response during episodes of atrial fibrillation. Dronedarone reduces mortality and morbidity in
patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure. This article will review
evidence of safety and effectiveness of dronedarone in patients with atrial fibrillation. (Circulation. 2009;120:636-644.)
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Atrial fibrillation (AF) is the most common arrhythmia inclinical practice and a usual cause for hospitalization
and consultation.1,2 It is an epidemic. It is projected that by
2050, more than 15 million people will contract AF in the
United States alone.2,3 Nearly 1 in every 10 persons aged 80
years and older has AF,1,4,5 predisposing them to stroke, heart
failure, and death.6,7 A recent report from Centers for Medi-
care and Medicaid Services suggested that AF accounted for
1 765 304 hospitalizations in 1999.8 The cost of medical care
for patients with AF is almost 5 times higher than the care of
patients without AF.9,10 Despite improvements in primary and
secondary prevention of ischemic heart disease and hyperten-
sion, the US age-adjusted death rate due to AF increased from
27.6 in 1980 to 69.8 per 100 000 in 1998.2,11
Current therapy for AF is multidimensional and compli-
cated.12 There is some consensus on the benefits of antico-
agulation in patients with AF, but debate continues about the
relative value of rate versus rhythm control. Recent clinical
trials have failed to demonstrate superiority of sinus rhythm
maintenance,13–18 but antiarrhythmic therapy is important for
patients with severe symptoms. Conventional antiarrhythmic
drugs have limited efficacy and safety. In fact, data suggest
that the benefit of restoring and maintaining sinus rhythm in
AF may be offset by significant cardiac and extracardiac side
effects of currently used drugs.19–21 Improvement in the
current approach to AF is clearly necessary. This review
focuses on dronedarone, a new antiarrhythmic drug for AF
suppression (Figure 1).
Electrophysiological Properties
of Dronedarone
In Vitro Experiments
In vitro electrophysiological properties of dronedarone and its
comparison with amiodarone are summarized in Table 1.23–33
In patch clamp experiments using human atrial myocytes, 3
mol/L of dronedarone produced potent blockade of peak
sodium current, an effect 10-fold greater than that of an equal
concentration of amiodarone.23 In guinea pig ventricular
myocytes, dronedarone inhibited the rapidly activating
delayed-rectifier potassium current, the slowly activating
delayed-rectifier potassium current, the inward rectifier po-
tassium current, and L-type calcium current.24 Additionally,
dronedarone exhibited strong inhibitory effects on the
acetylcholine-activated potassium current (IK-Ach) in rabbit
sinoatrial nodal cells32 and guinea pig atrial cells.31 Blockade
of IK-Ach by dronedarone was 100 times more potent than that
of amiodarone.31 A potent IK-Ach blocking property is of
additional therapeutic value especially for treatment of AF,
because IK-Ach plays a prominent role in vagally induced AF and
has been shown to be constitutively active in chronic AF.34,35
Like amiodarone, dronedarone exerts its antiadrenergic
effects by noncompetitive binding to -adrenergic receptors
and inhibition of agonist-induced increases in adenylate
cyclase activity.33 Dronedarone (0.01 to 1 mol/L) induced a
concentration-dependent reduction of coronary perfusion
pressure in isolated guinea pig hearts, effects that were
independent of the nitric oxide synthase pathway and possi-
bly related to its calcium current blockade.36
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The effect of dronedarone on single-cell cardiac action
potential is variable, depending on species and the duration of
drug administration. The most consistent effect is use-
dependent inhibition of maximum upstroke velocity, both
after acute and sustained administration. Acute administration
of 0.1 to 10 mol/L of dronedarone decreased action poten-
tial duration in rabbit papillary muscle,22 rabbit atrial mus-
cle,37 and the canine papillary muscle preparation,25 with no
effect on guinea pig ventricular myocytes.24 On the other
hand, sustained administration of drug increased action po-
tential duration in rabbit papillary muscles22 and rabbit atrial
muscles.37 The action potential duration of dog papillary
muscle remained unchanged.25 In canine left ventricular
Purkinje fibers, 10 mol/L of dronedarone reduced the
incidence of early and delayed afterdepolarizations evoked by
dofetilide and ouabain, respectively.25 Similarly, dronedarone
reduced transmural dispersion of repolarization and abolished
d-sotalol–induced early afterdepolarizations in canine left
ventricular tissue slices.38
Thus dronedarone has multichannel blocking properties
comparable to those of amiodarone. It is a more potent
blocker of peak sodium current and IK-Ach currents and has
stronger in vitro antiadrenergic effects compared with
amiodarone.
In Vivo Experiments
As with amiodarone, the effects of dronedarone on ventricu-
lar repolarization depend on duration of drug administration
and species. Although acute administration of dronedarone
abbreviates repolarization,39 sustained administration in-
creases the QTc interval.40 The difference in electrophysio-
logical effects between acute versus sustained administration
may be partially due to the fact that dronedarone and
amiodarone are highly protein-bound in vivo.41,42 Therefore,
it is difficult to directly extrapolate in vitro effects of
dronedarone to its in vivo actions.
In dogs with complete atrioventricular block, intravenous
administration of dronedarone shortened ventricular action
potential duration and suppressed almokalant-induced early
afterdepolarization, ectopic beats, and torsade de pointes.39
Sustained administration of dronedarone 20 mg/kg twice a
day for 4 weeks increased the QTc interval by 31% in the
same in vivo model.40 Similarly, sustained administration of
50 mg/kg per day of dronedarone for 4 weeks in rabbits
significantly prolonged the QT and R-R intervals and reduced
sinoatrial nodal automaticity.22 In contrast, chronic droneda-
rone treatment in the same dose in normal dogs did not
lengthen the QT interval significantly.25
In the rat model of ischemia and reperfusion-induced
arrhythmias, intravenous dronedarone, but not amiodarone,
prevented ventricular fibrillation.43 Similar findings were
reported in anesthetized pigs in which dronedarone proved
more potent than amiodarone in inhibiting ischemia-induced
ventricular arrhythmias.44
Studies in conscious and anesthetized dogs have shown
that dronedarone displays potent antiadrenergic activity, sim-
ilar to that of amiodarone.45,46 In conscious dogs with healed
myocardial infarctions, pretreatment with dronedarone re-
duced resting heart rate without compromising left ventricu-
lar function. Dronedarone was as effective as amiodarone in
reducing exercise- and isoprenaline-induced tachycardia.45
Pharmacokinetics
Dronedarone is well absorbed (70% to 94%) after oral
administration, and absorption increases 2- to 3-fold when it
is taken with food. Dronedarone undergoes significant first-
pass metabolism that reduces its net bioavailability to 15%.
With sustained administration of 400 mg twice daily, steady-
state plasma concentrations of 84 to 167 ng/mL are reached in
7 days.41 The clearance of dronedarone is principally nonre-
nal, with a terminal half-life of 24 hours.
Dronedarone is a substrate for and a moderate inhibitor of
CYP3A4.41 A potent CYP3A4 inhibitor such as ketoconazole
may increase dronedarone exposure by as much as 25-fold.
Consequently, dronedarone should not be coadministered
with potent CYP3A4 inhibitors like antifungals, macrolide
antibiotics, or protease inhibitors. When coadministered with
moderate CYP3A4 inhibitors such as verapamil and dilti-
azem, lower doses of concomitant drugs should be used to
avoid severe bradycardia and conduction block.41
Concomitant administration of dronedarone and digoxin
results in a 1.7- to 2.5-fold increase in serum digoxin
concentration, likely due to a P-glycoprotein–mediated inter-
action in the kidney.41 This necessitates frequent monitoring
of digoxin concentration and possible dose reduction. Coad-
ministration of dronedarone and simvastatin, a CYP3A4
Figure 1. Molecular structure of amiodarone, dronedarone, and
thyroxine. As compared with amiodarone, in the dronedarone
molecule, ethyl groups on the terminal nitrogen are replaced by
butyls groups, the iodine moiety is removed, and a methanesul-
fonyl group has been added to benzofuran ring. Reproduced
from Sun et al22 with permission from the publisher. Copyright
© 1999, the American Heart Association.
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substrate, leads to a 2- to 4-fold increase in simvastatin levels
and the potential for statin-induced myopathy.41
Dronedarone is also a CYP2D6 inhibitor and causes a
modest increase in bioavailability of metoprolol in CYP2D6
extensive metabolizers.47 Dronedarone, like amiodarone,
causes partial inhibition of tubular transport of creatinine,
which leads to increases in serum creatinine concentration
that is not related to reduced glomerular filtration.48
There are limited data available on dose response and dose
titration. On the basis of its pivotal clinical trials, dronedarone
can only be dosed at 400 mg twice daily. Adjustments in the
amount prescribed predicated on age, gender, race, renal
function, tolerance, or the use of concomitant interacting
drugs have not been studied and therefore cannot be
recommended.
Clinical Trials
A brief summary of clinical trials is provided in Table 2.
Clinical trials are categorized by their primary intention:
studies of rhythm control, rate control, mortality/morbidity,
or comparative efficacy.
Rhythm Control
The Dronedarone Atrial Fibrillation Study after Electrical
Cardioversion (DAFNE) was a double-blind, randomized,
placebo-controlled, dose-finding trial.49 A total of 270 pa-
tients with persistent AF were randomized to receive 800,
1200, or 1600 mg of dronedarone daily versus placebo and
were then followed for 6 months. There was a dose-
dependent conversion to sinus rhythm in 5.8%, 8.2%, and
14.8% of patients in the 3 dose groups, respectively, com-
pared with 3.1% in the placebo group. Dronedarone delayed
the time to first AF recurrence, but only at the lowest dose of
800 mg (Figure 2). At 6 months, 35% of patients treated with
800 mg of dronedarone were in sinus rhythm compared with
10% in the placebo group. In contrast to this reverse dose
effect on rhythm control, dronedarone reduced the ventricular
rate during AF better when used at high compared with low
doses.
In DAFNE, dronedarone was not associated with thyroid,
pulmonary, neurological, ocular, or pulmonary toxicity.
Dronedarone treatment led to dose-dependent prolongation of
QT interval, but no torsades de pointes cases were reported.
Dronedarone-treated patients, especially those treated with
the highest doses, had more gastrointestinal toxicity leading
to drug discontinuation.
The 400 mg twice daily dose of dronedarone was tested in
twin phase 3 studies called The European Trial in Atrial
Fibrillation or Flutter Patients Receiving Dronedarone for the
Maintenance of Sinus Rhythm (EURIDIS) and the American-
Australian-African Trial with Dronedarone in Atrial Fibrilla-
tion or Flutter Patients for the Maintenance of Sinus Rhythm
(ADONIS).50 The EURIDIS and ADONIS trials randomized
1237 patients in sinus rhythm, in a 2:1 ratio of active drug to
placebo. The mean age of the study population was 63 years.
Although the majority had structural heart disease, the mean
Table 1. Ion Channel Effects of Dronedarone and Its Comparison With Amiodarone
Current Tissue Dronedarone Amiodarone Comments
INa Human atrial myocytes 97% block at 3 mol/L23 41% block at 3 mol/L23 Dronedarone 10 times more
potent
ICa-L Guinea pig ventricular myocytes
Canine ventricular myocytes
Rabbit atrioventricular node
IC500.18 mol/L24
76% block at 10 mol/L25
85% block at 10 mol/L26
Use- and frequency-dependent
blockade
IKr Guinea pig ventricular myocytes IC50  3 mol/L24 IC5010 mol/L29 Voltage-independent blockade
Canine ventricular myocytes 97% block at 10 mol/L25
Xenopus laevis oocyte IC509.2 mol/L27
Mammalian cell system IC5059 nmol/L28 IC5070 nmol/L28 Voltage-dependent,
use-independent blockade
IKs Guinea pig ventricular myocytes
Xenopus laevis oocyte
IC5010 mol/L24
33% block at 100 mol/L27
IC5030 mol/L29 Voltage-dependent and time-,
frequency-, and
use-independent blockade
Cloned human KCNQ1/KCNE1
Ito Canine ventricular myocytes No effect at 10 mol/L25
Post-MI ventricular myocytes 20% increase at 1 mol/L30
IK1 Guinea pig ventricular myocytes IC5030 mol/L24 IC5030 mol/L29
IK-ACh Guinea pig atrial myocytes
Rabbit SA nodal cells
IC5010 nmol/L31
IC5063 nmol/L32
IC501 mol/L31 Dronedarone 100 times more
potent
-adrenergic receptors Rat heart IC50 1.8 mol/L33 IC508.7 mol/L33 Dose-dependent and
noncompetitive inhibition.
Agonist-induced increase in
adenylate cyclase was also
inhibited
IC50 indicates concentration that inhibits 50% of current; ICa-L, L type calcium current; IK-Ach, acetylcholine activated potassium current; IK1, inwardly rectified
potassium current; IKs, slowly activating delayed rectifier potassium current; IKr, rapidly activating delayed rectifier potassium current; INa, peak inward sodium current;
and SA, sinoatrial.
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Table 2. Summary of Clinical Trials Investigating Therapeutic Effects of Dronedarone
Study Inclusion Criteria
Specific Exclusion
Criteria Treatment Follow-Up
Results
Primary End Points Secondary End Points
DAFNE49 Persistent AF Permanent AF
Atrial flutter
NYHA class III or IV CHF
LVEF 35%
Placebo vs dronedarone
800, 1200, 1600
mg for 6 months
For 800 mg dose
Time to AF recurrence:
D: 60 days,
P: 5.3 days*
SR at end of 6 months:
D: 35%
P: 10%
Spontaneous conversion
to SR:
D: 5.8%
P: 3.1%*
VR during AF
recurrence:
Reduced by 13.2 bmp
EURIDIS and
ADONIS50
Paroxysmal AF Permanent AF
NYHA class III/IV CHF
Renal insufficiency
Placebo vs dronedarone
400 mg twice
daily for 12 months
Time to AF recurrence:
D: 116 days
P: 53 days*
Recurrence rate of AF:
D: 64.1%
P: 75.2%*
VR during AF
recurrence:
D:103.4 25.9
P: 117.1 30.4*
Symptomatic AF
recurrence:
D: 37.7%
P: 46%*
Hospitalization or death:
D: 22.8%
P: 30.9%*
ERATO51 Permanent AF NYHA class III/IV CHF Placebo vs dronedarone
400 mg twice
daily for 6 months
Mean VR on 14th day:
Reduced by 11.7 bpm*
Change in Mean VR on
14th day during exercise:
Reduced by 24.5 bpm*
Change in mean resting
VR at 4 months:
Reduced by 8.8 bpm*
ANDROMEDA52 NYHA class III/IV CHF or
PND plus
LVEF 35%
Recent acute MI
Acute pulmonary Edema
Placebo vs dronedarone
400 mg twice daily for 12
months
Death from any cause
or
hospitalization from
worsening
heart failure:
D: 17.1%
P: 12.6%
HR1.38
Death from all cause:
D: 8.1%
P: 3.8%* (HR2.13*)
Cardiovascular
hospitalization:
D: 22.9%
P: 15.7%*
ATHENA53–55 Paroxysmal/persistent
AF/atrial flutter
plus
age 75
or
age701 risk factor
(HTN, DM, stroke, TIA,
LA 50 mm or
LVEF 40%)
Permanent AF
Unstable hemodynamic
situation
NYHA class IV CHF
Placebo vs dronedarone
400 mg twice
daily for 12 months
Death from all causes
or first
occurrence of
cardiovascular
hospitalization:
24.2% RR reduction*
HR: 0.76*
Death from any cause:
16% fewer deaths with
dronedarone
Cardiovascular deaths:
29% RR reduction*
Cardiovascular
hospitalization:
26% RR reduction*
Incidence of stroke:
34% RR reduction*
Length of
hospitalization:
Reduced by 1.26
day/patient/year*
DIONYSOS56 Persistent AF Not reported yet Dronedarone
400 mg twice daily
vs amiodarone 600
mg/day for 28 days
followed by 200 mg daily
for 6 months
AF recurrence or
premature drug
discontinuation for
intolerance or
lack of efficacy:
D: 73.9%
Amiodarone: 55.3%*
MSE:
20% decrease favoring
dronedarone
MSE excluding
gastrointestinal side
effects:
39% decrease favoring
dronedarone*
D indicates dronedarone; P, placebo; AF, atrial fibrillation; bpm, beats per minute; CV, cardiovascular; CHF, congestive heart failure; DM, diabetes mellitus; HTN, hypertension; HR, hazard ratio; LA, left atrium; LVEF,
left ventricular ejection fraction; MI, myocardial infarction; MSE, Main Safety End points; NYHA, New York heart association; PND, paroxysmal nocturnal dyspnea; RR, relative risk; SR, sinus rhythm; TIA, transient ischemic
attack; and VR, ventricular rate.
*Statistically significant P value.
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left ventricular ejection fraction was 58%, and only 17% of
patients had a history of class I or II congestive heart failure.
Ventricular rate and rhythm were monitored by a 12-lead
ECG at each scheduled follow-up visit and using transtele-
phonic electrocardiographic monitoring.
In a prespecified pooled analysis, the median time to first
recurrence of AF was 116 days in the dronedarone arm versus
53 days in the placebo group (Figure 3). Dronedarone
reduced the ventricular rate during AF recurrence. A post hoc
analysis revealed a 27% reduction of relative risk of hospi-
talization and death with dronedarone treatment. The rates of
cardiac and extracardiac adverse events in these trials were
comparable to those of the placebo. There was a reported
incidence of serum creatinine elevation in 2.4% of the
patients in dronedarone group.
Additionally, a small study in patients with implantable
cardiac defibrillators found that dronedarone at doses of up to
2000 mg daily had no significant effect on defibrillation and
pacing thresholds. There was a trend toward a reduction in
appropriate implantable cardiac defibrillators shocks at the
highest doses, which were poorly tolerated.57
Rate Control
Efficacy and Safety of Dronedarone for Control of Ventric-
ular Rate (ERATO)51 was a study of the efficacy of drone-
darone for rate control in patients with permanent AF.
ERATO investigators randomized 174 elderly patients to 800
mg of dronedarone daily or placebo. Despite prior rate-
control therapy with -blockers, digitalis, or calcium channel
antagonists, all patients at study entry had a resting heart rate
of 80 beats per minute. The majority again had structural
heart disease, but none had severe heart failure.
In the ERATO trial, the addition of dronedarone to stan-
dard rate-control therapy reduced the ventricular rate by 11.7
beats per minute on day 14, and the effect was sustained for
the 6-month trial period (Figure 4). More pronounced rate
control was seen during exercise (mean reduction of 24.5
beats per minute, Figure 4), but this did not translate into
improved exercise duration. There were no untoward inter-
actions between dronedarone and other rate control agents or
anticoagulants, except for a 41% increase in serum digoxin
concentration.51
Mortality and Morbidity
Antiarrhythmic Trial with Dronedarone in Moderate-to-
Severe Congestive Heart Failure Evaluating Morbidity De-
crease (ANDROMEDA) was a mortality trial in which
dronedarone was compared with placebo in patients with
moderate to severe heart failure, regardless of their arrhyth-
mia history.52 One thousand hospitalized patients with New
York Heart Association class III or IV congestive heart
failure and left ventricular ejection fraction 35% were to
receive 800 mg of dronedarone daily or placebo. After 627
patients were enrolled, the trial was prematurely terminated.
During a median follow-up of 2 months, a significantly
higher mortality rate was reported with dronedarone treat-
ment (8.1%) as compared with placebo (3.8%), primarily due
to worsening congestive heart failure. The risk of death and
hospitalization was higher in patients with the most severe
left ventricular systolic dysfunction. A retrospective analysis
identified a higher death rate in patients who were withdrawn
from angiotensin-converting enzyme inhibitors and/or angio-
tensin receptor blockers, but how much this contributed to the
death imbalance is uncertain. Potent inhibition of peak
sodium current and resultant impairment of ventricular con-
tractility may be another possible explanation for worsening
heart failure.23
Assess the Efficacy of Dronedarone for the Prevention of
Cardiovascular Hospitalization or Death from Any Cause in
Patients with Atrial Fibrillation/Atrial Flutter (ATHENA)
enrolled patients with stable AF who had at least 1 cardio-
Figure 3. Dronedarone reduces the recurrence rate of atrial
fibrillation. Kaplan–Meier cumulative incidence curve for the
adjudicated first recurrence of atrial fibrillation. At 12 months,
the rates of recurrence were 64.1% in the dronedarone group
and 75.2% in the placebo group (hazard ratio 0.75; 95% CI,
0.65 to 0.87; P0.001). Combined data from EURIDIS and
ADONIS trial. Modified and reproduced from Singh et al50 with
permission of the publisher. Copyright © 2007, the Massachu-
setts Medical Society.
Figure 2. Dronedarone increases the time to first recurrence of
atrial fibrillation. Kaplan–Meier analysis of the time to first AF recur-
rence to assigned treatment. The median time to first AF recur-
rence was significantly delayed to 60 days in patients receiving
800 mg of dronedarone as compared with patients receiving pla-
cebo (5.3 days), with relative risk reduction of 55% (P0.001).
Data from DAFNE trial. Reproduced from Touboul et al49 with per-
mission of the publisher. Copyright © 2003, Oxford University
Press.
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vascular risk factor.54 Unlike prior studies, this trial had a
composite primary end point of all-cause mortality and
cardiovascular hospitalization. ATHENA investigators ran-
domized 4628 patients with a history of paroxysmal or
persistent AF/atrial flutter to dronedarone 400 mg twice a day
versus placebo with 12 months of follow-up.
The results of the ATHENA trial are shown in Figure 5.54
Treatment with dronedarone was associated with highly
Figure 4. Dronedarone reduces the mean ventricular rate during rest (A) and exercise (B) in atrial fibrillation. Treatment with dronedar-
one reduced the mean 24-hour ventricular rate by 11.7 beats/min during rest and by 24.5 beats/min during exercise on day 14. Data
from ERATO trial. Modified and reproduced from Davy et al,51 copyright © 2008, with permission from Elsevier.
Figure 5. Kaplan–Meier cumulative incidences of the primary and secondary outcomes in the ATHENA trial. Treatment with dronedar-
one significantly reduced the occurrence of (A) the composite primary outcome of first hospitalization due to cardiovascular events or
death from any cause (hazard ratio [HR] 0.76), (C) secondary outcomes of death from cardiovascular causes (HR 0.71), and (D) first
hospitalization due to cardiovascular events (HR 0.74). (B) There was no difference in all-cause mortality (HR 0.84). Reproduced from
Hohnloser et al54 with permission from the publisher. Copyright © 2009, the Massachusetts Medical Society.
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statistically significant reductions in the primary end point
and several of the secondary end points. There was a trend
toward lower overall mortality with dronedarone treatment,
and, importantly, there was a statistically significant reduc-
tion in death due to cardiac arrhythmias (hazard ratio 0.55;
P0.01). Because dronedarone blocks sodium current as well
as multiple potassium currents, it increases the ventricular
effective refractory period, which may account for ventricular
arrhythmia suppression.43,44 The most frequently reported
adverse effect of dronedarone was gastrointestinal, princi-
pally nausea and diarrhea that in several cases led to drug
discontinuation (Table 3). The reduction in cardiovascular
hospitalizations was accounted for mostly by fewer admis-
sions for AF. A post hoc analysis demonstrated that drone-
darone was associated with a significant reduction in the
adjusted risk of stroke compared with placebo, a benefit that
was preserved in patients who were already receiving anti-
thrombotic therapy.53
Comparative Efficacy
A clinical trial directly comparing dronedarone with amiod-
arone for maintenance of sinus rhythm in AF called Efficacy
and Safety of Dronedarone versus Amiodarone for the main-
tenance of Sinus Rhythm in Patients with AF (DIONYSOS)
recently concluded. The results have not been presented in
full.56 DIONYSOS randomized 504 patients with persistent
AF to dronedarone (400 mg BID) versus amiodarone (600 mg
daily for 28 days and then 200 mg daily) for a minimum of 6
months. The primary end point was a composite of ECG-
documented AF recurrence or premature study drug discon-
tinuation for intolerance or lack of efficacy. At a mean
follow-up of 7 months, fewer amiodarone-treated patients
reached the primary end point compared with those treated
with dronedarone (55.3% versus 73.9%, P0.001), indicat-
ing that amiodarone showed better sustained efficacy than
dronedarone. More gastrointestinal adverse events (diarrhea,
vomiting, and nausea) and fewer cardiac adverse events
(bradycardia, QT prolongation) were noted in the dronedar-
one arm.
Conclusions
Like amiodarone, dronedarone has effects on multiple cardiac
ion channels and receptors. In several clinical trials, drone-
darone has been proven to maintain sinus rhythm and to
control the ventricular rate during episodes of AF. In
ATHENA, dronedarone reduced cardiovascular hospitaliza-
tions and mortality in high-risk patients with AF.53,55 Drone-
darone has a well-described side effect profile; the principle
adverse effect is diarrhea, which may necessitate drug dis-
continuation. Dronedarone causes dose-dependent prolonga-
tion of QTc interval, but torsades de pointes is rare.49,50,54 The
drug increases serum creatinine by inhibition of tubular
secretion. This effect is not associated with reduced renal
function and is reversible, but needs to be considered,
particularly in patients receiving other drugs like angioten-
sin-converting enzyme inhibitors that also increase serum
creatinine.48
The safety of dronedarone in patients with advanced heart
failure is a concern.52 Although ATHENA included patients
with heart failure, it excluded severely ill patients with
advanced heart failure and hemodynamic instability. Only
4.4% subjects in ATHENA had New York Heart Association
class III heart failure, and only 3.9% patients had left
ventricular ejection fraction 35%. Therefore, the results of
the ATHENA trial do not directly counter the concerns raised
by the ANDROMEDA trial. Until more data are available,
patients with severe systolic heart failure and hemodynamic
instability should not receive dronedarone.
As of this writing, dronedarone is under review by regu-
latory agencies. It is likely to be available for patients with
AF with severe associated symptoms, in particular those with
risk factors for stroke and heart failure. Although not a
panacea, it will provide another useful option for patients
afflicted with this common and troubling disease.
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Dronedarone
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Any TEAE 72.0 69.3 0.048
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QT-interval prolongation 1.7 0.6 0.001
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Rash 3.4 2.0 0.006
Serum creatinine increase 4.7 1.3 0.001
Any serious TEAE 19.9 21.1 0.31
Premature discontinuation of
study drug because of
an adverse event
12.7 8.1 0.001
TEAEs indicates treatment-emergent adverse events.
Data borrowed from Hohnloser et al.54
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